Literature DB >> 3147904

Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects.

G Ollenschläger1, E Roth, W Linkesch, S Jansen, A Simmel, B Mödder.   

Abstract

Several side-effects of asparaginase therapy have been said to be a consequence of the glutaminase activity of Escherichia coli asparaginase, especially the deleterious influence on the liver function. We report here the drug-induced impairments of asparagine and glutamine metabolism in correlation to concentrations changes of plasma proteins, synthesized in the liver, in patients with acute lymphatic leukaemia. One hour after asparaginase application, plasma glutamine decreased to 5% (0-39%: median, range) of the initial values, with a subsequent rise to concentrations slightly lower than those prior to therapy. During the 14 days of drug application the fasting plasma concentrations of glutamine fell to a median of 63% of the pre-therapeutic levels, indicating a depletion of the glutamine pools. Two days after the end of asparaginase application, in one patient the glutamine concentrations increased to the pre-therapeutic range. Plasma concentrations of fibrinogen and antithrombin III decreased to 46% and 56%, respectively, of the initial values, with a slight increase 2 days after the end of therapy. The changes of plasma protein concentrations followed the course of plasma glutamine and asparagine. From that we deduce that the hepatic synthesis of the plasma proteins might be influenced by asparagine and glutamine depletion as a consequence of the therapy with E. coli asparaginase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147904     DOI: 10.1111/j.1365-2362.1988.tb01049.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  32 in total

1.  Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.

Authors:  Hien Anh Nguyen; Ying Su; Arnon Lavie
Journal:  J Biol Chem       Date:  2016-06-27       Impact factor: 5.157

2.  The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.

Authors:  Wai Kin Chan; Philip L Lorenzi; Andriy Anishkin; Preeti Purwaha; David M Rogers; Sergei Sukharev; Susan B Rempe; John N Weinstein
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

Review 3.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

4.  Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.

Authors:  C Derst; J Henseling; K H Röhm
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

Review 5.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716

Review 6.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

7.  The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.

Authors:  Gabriel J Wilson; Piyawan Bunpo; Judy K Cundiff; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-03       Impact factor: 4.310

8.  GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.

Authors:  Gabriel J Wilson; Brittany A Lennox; Pengxiang She; Emily T Mirek; Rana J T Al Baghdadi; Michael E Fusakio; Joseph L Dixon; Gregory C Henderson; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-12-09       Impact factor: 4.310

9.  GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase.

Authors:  Piyawan Bunpo; Allison Dudley; Judy K Cundiff; Douglas R Cavener; Ronald C Wek; Tracy G Anthony
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

Review 10.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.